Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tarenflurbil in mild Alzheimer's disease
2006-000654-43Phase 3Completed
- Sponsor
- Myrexis, Inc.
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing tarenflurbil with placebo (2 arms). Primary endpoints: Change from baseline in Alzheimer's Disease Assessment Scale cognitive subscale and Change from baseline in Alzheimer's Disease Cooperative Study activities of daily living scale. Started Mar 2006; status: completed.
02
Drugs
tarenflurbil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-000654-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000654-43.